preterm birth
Sera Prognostic Shares Spike on Promising Interim Results in Study for Preterm Birth Test
In trading on Nasdaq, Sera shares rose as high as $9.86 after closing Tuesday at $2.10. In mid-afternoon trading, shares were up more than threefold to $6.34.
Sera Prognostics Shares Spike on Positive Study Results for PreTRM Preterm Birth Test
The company said the study met its two primary outcomes of reducing severe neonatal morbidity or neonatal death and decreasing the length of neonatal hospital stays.
Mirvie Raises $60M in Series B Funding
The company plans to use the funding to propel the clinical and commercial development of its Mirvie RNA testing platform for pregnancy health.
The South San Francisco-based startup recently published two studies showing the performance of its tests for predicting preterm birth and preeclampsia.
Oppenheimer Initiates Coverage of Sera Prognostics at Outperform
The investment bank said Sera's primary product has the potential to create a new market for blood-based testing to assess preterm birth risk.